Reva Medical (ASX:RVA) inked a distribution deal with Kardionet Healthcare & Foreign Trading to launch commercial operations in Turkey for its bioresorbable scaffold tech, the company reported today.
According to the terms of the deal, Kardionet will be responsible for sales, marketing, customer training and support for Reva’s Fantom and Fantom Encore bioresorbable devices in Turkey. The San Diego, Calif.-based company expects to start selling the scaffolds in the second quarter of 2018.
“We are very excited to bring the Fantom bioresorbable scaffold to patients in Turkey. We believe that it will be well received by physicians, who have experience with first generation bioresorbable scaffolds and have expressed interest in Fantom’s x-ray visibility, thinner strut profile, and improved ease-of-use,” Carmelo Mastrandrea, Reva’s VP of Europe, said in prepared remarks. “Kardionet’s proven success with interventional cardiology devices and their demonstrated support of patients and physicians make them an ideal distributor for us in Turkey.”
“Reva’s top corporate priority is ensuring Fantom’s commercial success. We began our first phase of launch with our direct sales force in Germany, Switzerland, and Austria last year. The distribution agreement with Kardionet marks the start of our second phase of launch for Fantom,” CEO Reggie Groves added.
Last month, Reva touted that its Fantom Encore device was used for the first time in Switzerland. The sirolimus-eluting device, which is made from Reva’s proprietary Tyrocore polymer, features a 95-micron strut profile and x-ray visibility.
The company launched its commercial operations in Switzerland last year and has since won CE Mark approval in the European Union for its Fantom Encore device.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.